Short Interest Update on Catalyst Pharmaceuticals (CPRX)

Catalyst Pharmaceuticals (CPRX) has 1,796,463 shares of shorts outstanding as on August 15, 2016, with 5 days left to cover or roll them over. On Jul 29, 2016, the open interest of short positions was 2,113,637 shares. The stock has a decent trading volume of 389,072 shares daily. The marginal decrease in the short positions is by -15%, which amounts to -317,174 shares. Short positions are 2.6% of the available float. The short interest information was released on Wednesday Aug 24th after the market close.

Catalyst Pharmaceuticals (NASDAQ:CPRX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $1.00 and $0.99 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $1.20. The buying momentum continued till the end and the stock did not give up its gains. It closed at $1.06, notching a gain of 3.92% for the day. The total traded volume was 3,383,807 . The stock had closed at $1.02 on the previous day.


In a related news, OKeeffe Charles B, director of Catalyst Pharmaceuticals, Inc., executed a transaction worth $16,200 on July 12, 2016. A total of 20,000 shares were purchased at an average price of $0.81. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. Firdapse is used for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). CPP-115 is used for the treatment of addiction and epilepsy. CPP-109 is used to treat addiction. The Company is conducting a Phase III trial to determine the safety and efficacy of Firdapse in the treatment of LEMS. CPP-115 has been granted Orphan Drug Designation by the food and drug administration (FDA) for the treatment of infantile spasms and Orphan Medicinal Product Designation in the European Union, for West syndrome (a form of infantile spasms).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.